

1 WHAT IS CLAIMED IS:

2

3 1. A method for immunizing an animal against heterologous HIV-1 comprising
4 administering to said animal an immunogen comprising at least one modified HIV-1
5 envelope protein or fragment thereof, or DNA or virus encoding said at least one
6 modified HIV-1 envelope protein or fragment thereof, or a combination thereof, said
7 modified envelope protein or fragment thereof having a V2 region deletion, wherein
8 said animal exhibits immunity to at least one HIV-1 strain other than that of said
9 immunogen.

10 2. The method of claim 1 wherein said immunity comprises a humoral response.

11 3. The method of claim 1 wherein said immunogen comprises a modified HIV-1
12 envelope protein from a clade-B HIV-1 strain.

13 4. The method of claim 3 wherein said HIV-strain is SF162.

14 5. The method of claim 4 wherein said modified HIV-1 envelope protein is SEQ ID
15 No:2 or SEQ ID No:4.

16 5. The method of claim 4 wherein said DNA encoding said at least one modified HIV-1
17 envelope protein is SEQ ID No:1 or SEQ ID No:3.

18 6. The method of claim 2 wherein said humoral response comprises neutralizing
19 antibodies.

4 8. The method of claim 1 wherein said animal is a human.

4 8. The method of claim 1 wherein said animal is a human.

5

6 9. A method for eliciting a heterologous immune response to HIV-1 in an animal

7 comprising immunizing said animal with an immunogen comprising at least one

8 modified HIV-1 envelope protein or fragment thereof, or DNA or virus encoding said

9 at least one modified HIV-1 envelope protein or fragment thereof, or a combination

10 thereof, said modified envelope protein or fragment thereof having a V2 region

11 deletion, wherein said animal exhibits a an envelope-specific immune response to at

12 least one HIV-1 strain other than that of said immunogen.

14. 10. The method of claim 9 wherein said envelope-specific immune response comprises a
15. humoral response.

16
17 11. The method of claim 9 wherein said immunog
18 envelope protein from a clade-B HIV-1 strain.

20 12. The method of claim 11 wherein said HIV-strain is SF162.

22 13. The method of claim 12 wherein said modified HIV-1 envelope protein is SEQ ID
23 No:2 or SEQ ID No:4.

25 14. The method of claim 12 wherein said DNA encoding said at least one modified HIV-1
26 envelope protein is SEO ID No:1 or SEO ID No:3.

1
2 15. The method of claim 10 wherein said humoral response comprises neutralizing
3 antibodies.
4

5 16. The method of claim 10 wherein said humoral response comprises protective
6 antibodies.
7

8 17. The method of claim 9 wherein said animal is a human.
9

10 18. A pharmaceutical composition for immunizing an animal against HIV-1 virus
11 comprising an effective heterologous envelope-specific immune response-eliciting
12 amount of at least one modified HIV-1 envelope protein or fragment thereof, or DNA
13 or virus encoding said at least one modified HIV-1 envelope protein or fragment
14 thereof, or a combination thereof, said modified envelope protein or fragment thereof
15 having a V2 region deletion; and a pharmaceutically-acceptable carrier or excipient.
16

17 19. The pharmaceutical composition of claim 18 wherein said modified HIV-1 envelope
18 protein is from a clade-B HIV-1 strain.
19

20 20. The pharmaceutical composition of claim 19 wherein said HIV-1 strain is SF162.
21

22 21. The pharmaceutical composition of claim 20 wherein said modified HIV-1 envelope
23 protein is SEQ ID No:2 or SEQ ID No:4.
24

25 22. The pharmaceutical composition of claim 20 wherein said DNA encoding said at least
26 one modified HIV-1 envelope protein is SEQ ID No:1 or SEQ ID No:3.

1

2 23. A method for assessing whether a compound is capable of generating protective
3 antibodies in an animal against at least one heterologous strain of HIV-1, said animal
4 capable of developing protective antibodies against wild-type HIV-1, said method
5 comprising the steps of immunizing said animal with said compound, depleting said
6 animal of its CD8+ T-lymphocytes, and assessing the presence of protective
7 antibodies in the said animal to at least one heterologous strain of HIV-1.

8

9 24. The method of claim 23 wherein said depleting is carried out by administering to said
10 animal anti-CD8 monoclonal antibodies.

11

12 25. The method of claim 23 wherein said compound is an HIV-derived polypeptide or
13 fragment thereof or a DNA or virus encoding said peptide or fragment thereof.

14

15 26. The method of claim 23 wherein said immunizing is carried out with a DNA vaccine,
16 a protein, or a combination thereof.

17

18 27. The method of claim 23 wherein said neutralizing antibodies are protective
19 antibodies.

20